1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5.
Global Pigmentation
Disorders Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1.
By Value
5.2. Market Share & Forecast
5.2.1.
By Indication
(Hyperpigmentation, Hypopigmentation)
5.2.2.
By Treatment & Therapies
(Chemical Peels, Dermabrasion, Laser Resurfacing, Melasma)
5.2.3.
By End User
(Dermatology Clinics, Hospitals),
5.2.4.
By Company (2022)
5.3. Market Map
6.
Asia Pacific Pigmentation
Disorders Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1.
By Value
6.2. Market Share & Forecast
6.2.1.
By Indication
6.2.2.
By Treatment & Therapies
6.2.3.
By End User
6.2.4.
By Country
6.3. Asia Pacific: Country Analysis
6.3.1.
China Pigmentation
Disorders Treatment Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Indication
6.3.1.2.2.
By Treatment & Therapies
6.3.1.2.3.
By End User
6.3.2.
India Pigmentation
Disorders Treatment Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Indication
6.3.2.2.2.
By Treatment & Therapies
6.3.2.2.3.
By End User
6.3.3.
Australia Pigmentation
Disorders Treatment Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Indication
6.3.3.2.2.
By Treatment & Therapies
6.3.3.2.3.
By End User
6.3.4.
Japan Pigmentation
Disorders Treatment Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Indication
6.3.4.2.2.
By Treatment & Therapies
6.3.4.2.3.
By End User
6.3.5.
South Korea Pigmentation
Disorders Treatment Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Indication
6.3.5.2.2.
By Treatment & Therapies
6.3.5.2.3.
By End User
7.
Europe Pigmentation
Disorders Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1.
By Value
7.2. Market Share & Forecast
7.2.1.
By Indication
7.2.2.
By Treatment & Therapies
7.2.3.
By End User
7.2.4.
By Country
7.3. Europe: Country Analysis
7.3.1.
France Pigmentation
Disorders Treatment Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Indication
7.3.1.2.2.
By Treatment & Therapies
7.3.1.2.3.
By End User
7.3.2.
Germany Pigmentation
Disorders Treatment Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Indication
7.3.2.2.2.
By Treatment & Therapies
7.3.2.2.3.
By End User
7.3.3.
Spain Pigmentation
Disorders Treatment Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Indication
7.3.3.2.2.
By Treatment & Therapies
7.3.3.2.3.
By End User
7.3.4.
Italy Pigmentation
Disorders Treatment Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Indication
7.3.4.2.2.
By Treatment & Therapies
7.3.4.2.3.
By End User
7.3.5.
United Kingdom Pigmentation
Disorders Treatment Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Indication
7.3.5.2.2.
By Treatment & Therapies
7.3.5.2.3.
By End User
8.
North America Pigmentation
Disorders Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1.
By Value
8.2. Market Share & Forecast
8.2.1.
By Indication
8.2.2.
By Treatment & Therapies
8.2.3.
By End User
8.2.4.
By Country
8.3. North America: Country Analysis
8.3.1.
United States Pigmentation
Disorders Treatment Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Indication
8.3.1.2.2.
By Treatment & Therapies
8.3.1.2.3.
By End User
8.3.2.
Mexico Pigmentation
Disorders Treatment Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Indication
8.3.2.2.2.
By Treatment & Therapies
8.3.2.2.3.
By End User
8.3.3.
Canada Pigmentation
Disorders Treatment Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Indication
8.3.3.2.2.
By Treatment & Therapies
8.3.3.2.3.
By End User
9.
South America Pigmentation
Disorders Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1.
By Value
9.2. Market Share & Forecast
9.2.1.
By Indication
9.2.2.
By Treatment & Therapies
9.2.3.
By End User
9.2.4.
By Country
9.3. South America: Country Analysis
9.3.1.
Brazil Pigmentation
Disorders Treatment Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Indication
9.3.1.2.2.
By Treatment & Therapies
9.3.1.2.3.
By End User
9.3.2.
Argentina Pigmentation
Disorders Treatment Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Indication
9.3.2.2.2.
By Treatment & Therapies
9.3.2.2.3.
By End User
9.3.3.
Colombia
Pigmentation Disorders Treatment Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Indication
9.3.3.2.2.
By Treatment & Therapies
9.3.3.2.3.
By End User
10.
Middle East and Africa
Pigmentation Disorders Treatment Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share &
Forecast
10.2.1. By
Indication
10.2.2. By
Treatment & Therapies
10.2.3. By End
User
10.2.4. By Country
10.3.
MEA: Country
Analysis
10.3.1. South Africa Pigmentation Disorders Treatment
Market Outlook
10.3.1.1. Market Size &
Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share &
Forecast
10.3.1.2.1.
By Indication
10.3.1.2.2.
By Treatment & Therapies
10.3.1.2.3.
By End User
10.3.2. Saudi Arabia Pigmentation Disorders Treatment
Market Outlook
10.3.2.1. Market Size &
Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share &
Forecast
10.3.2.2.1.
By Indication
10.3.2.2.2.
By Treatment & Therapies
10.3.2.2.3.
By End User
10.3.3. UAE Pigmentation Disorders Treatment Market
Outlook
10.3.3.1. Market Size &
Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share &
Forecast
10.3.3.2.1.
By Indication
10.3.3.2.2.
By Treatment & Therapies
10.3.3.2.3.
By End User
11. Market Dynamics
11.1.
Drivers
11.2.
Challenges
12. Market Trends & Developments
12.1.
Recent Developments
12.2.
Product Launches
12.3.
Mergers &
Acquisitions
13. Global Pigmentation Disorders Treatment Market:
SWOT Analysis
14.
Porter’s Five Forces
Analysis
14.1.
Competition in the
Industry
14.2.
Potential of New
Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute
Product
15. PESTLE Analysis
16. Competitive Landscape
16.1.
Zerigo Health.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2.
Bausch Health
Companies Inc.
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products & Services
16.2.4. Financials (In case of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3.
Glenmark
Pharmaceuticals Limited
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products & Services
16.3.4. Financials (In case of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4.
Novartis AG
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products & Services
16.4.4. Financials (In case of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5.
Pfizer Inc.
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products & Services
16.5.4. Financials (In case of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6.
Teva Pharmaceutical
Industries Ltd.
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products & Services
16.6.4. Financials (In case of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7.
Bayer AG
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products & Services
16.7.4. Financials (In case of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8.
CLINUVEL
PHARMACEUTICALS LTD
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products & Services
16.8.4. Financials (In case of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9. Strides Pharma Science Limited
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products & Services
16.9.4. Financials (In case of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis
16.10.Astellas Pharma Inc.
16.10.1. Business Overview
16.10.2. Company Snapshot
16.10.3. Products & Services
16.10.4. Financials (In case of listed companies)
16.10.5. Recent Developments
16.10.6. SWOT Analysis
17.
Strategic Recommendations
18. About Us & Disclaimer